CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
5.33
1.84%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Thu: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Immunitybio Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 5.43
Open* 5.5
1-Year Change* 225.44%
Day's Range* 5.33 - 5.75
52 wk Range 1.21-6.93
Average Volume (10 days) 3.16M
Average Volume (3 months) 129.61M
Market Cap 2.42B
P/E Ratio -100.00K
Shares Outstanding 667.71M
Revenue 556.00K
EPS -1.05
Dividend (Yield %) N/A
Beta 1.05
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 5.43 0.26 5.03% 5.17 5.43 4.57
Mar 26, 2024 5.10 -0.40 -7.27% 5.50 5.62 5.07
Mar 25, 2024 5.41 -0.69 -11.31% 6.10 6.19 5.34
Mar 22, 2024 6.05 -0.17 -2.73% 6.22 6.76 5.86
Mar 21, 2024 6.12 0.02 0.33% 6.10 6.26 5.66
Mar 20, 2024 5.96 0.49 8.96% 5.47 6.17 5.47
Mar 19, 2024 5.39 0.28 5.48% 5.11 5.44 5.03
Mar 18, 2024 5.21 0.06 1.17% 5.15 5.34 4.99
Mar 15, 2024 5.14 0.14 2.80% 5.00 5.19 4.86
Mar 14, 2024 4.90 -0.11 -2.20% 5.01 5.17 4.84
Mar 13, 2024 5.07 0.08 1.60% 4.99 5.23 4.93
Mar 12, 2024 5.04 -0.16 -3.08% 5.20 5.27 5.04
Mar 11, 2024 5.10 -0.29 -5.38% 5.39 5.51 5.09
Mar 8, 2024 5.46 0.33 6.43% 5.13 5.52 4.92
Mar 7, 2024 5.02 -0.03 -0.59% 5.05 5.21 4.87
Mar 6, 2024 5.06 0.05 1.00% 5.01 5.13 4.89
Mar 5, 2024 4.80 -0.18 -3.61% 4.98 5.30 4.80
Mar 4, 2024 5.05 0.29 6.09% 4.76 5.07 4.47
Mar 1, 2024 4.67 -0.07 -1.48% 4.74 4.99 4.67
Feb 29, 2024 4.70 0.11 2.40% 4.59 4.97 4.58

ImmunityBio, Inc. Events

Time (UTC) Country Event
Thursday, May 9, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Immunitybio Inc Earnings Release
Q1 2024 Immunitybio Inc Earnings Release

Forecast

-

Previous

-
Wednesday, June 12, 2024

Time (UTC)

16:30

Country

US

Event

Immunitybio Inc Annual Shareholders Meeting
Immunitybio Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.24 0.934 0.605 2.202 0.047
Revenue 0.24 0.934 0.605 2.202 0.047
Total Operating Expense 351.538 331.214 221.485 158.453 98.436
Selling/General/Admin. Expenses, Total 103.508 135.856 71.818 46.456 42.918
Research & Development 245.449 195.358 139.007 111.997 53.218
Operating Income -351.298 -330.28 -220.88 -156.251 -98.389
Interest Income (Expense), Net Non-Operating -63.766 -19.264 -5.781 -3.481 1.887
Other, Net -2.222 -0.295 0.628 -0.531 -0.227
Net Income Before Taxes -417.286 -349.839 -226.033 -160.263 -96.729
Net Income After Taxes -417.32 -349.848 -224.187 -160.158 -96.226
Net Income Before Extra. Items -416.567 -346.79 -221.851 -157.777 -96.226
Net Income -416.567 -346.79 -221.851 -157.777 -96.226
Income Available to Common Excl. Extra. Items -416.567 -346.79 -221.851 -157.777 -96.226
Income Available to Common Incl. Extra. Items -416.567 -346.79 -221.851 -157.777 -96.226
Diluted Net Income -416.567 -346.79 -221.851 -157.777 -96.226
Diluted Weighted Average Shares 399.9 389.234 377.068 366.325 79.1322
Diluted EPS Excluding Extraordinary Items -1.04168 -0.89095 -0.58836 -0.4307 -1.21602
Diluted Normalized EPS -1.03878 -0.89095 -0.56998 -0.4307 -1.21602
Depreciation / Amortization 1.9 2.3
Total Extraordinary Items 0
Unusual Expense (Income) 0.681 0 10.66 0
Minority Interest 0.753 3.058 2.336 2.381
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.041 0.36 0.073 0.118 0.035
Revenue 0.041 0.36 0.073 0.118 0.035
Total Operating Expense 85.186 111.94 84.973 90.922 79.657
Selling/General/Admin. Expenses, Total 32.018 32.676 26.215 19.31 16.575
Research & Development 52.668 78.764 57.577 71.012 62.482
Operating Income -85.145 -111.58 -84.9 -90.804 -79.622
Interest Income (Expense), Net Non-Operating -52.78 -4.186 -22.496 -20.353 -14.944
Other, Net -0.288 -0.817 -0.896 -0.004 -0.269
Net Income Before Taxes -138.213 -116.583 -108.292 -111.161 -94.835
Net Income After Taxes -138.213 -116.583 -108.326 -111.161 -94.835
Minority Interest 0.334 0.24 0.111 0.223 0.247
Net Income Before Extra. Items -137.879 -116.343 -108.215 -110.938 -94.588
Net Income -137.879 -116.343 -108.215 -110.938 -94.588
Income Available to Common Excl. Extra. Items -137.879 -116.343 -108.215 -110.938 -94.588
Income Available to Common Incl. Extra. Items -137.879 -116.343 -108.215 -110.938 -94.588
Diluted Net Income -137.879 -116.343 -108.215 -110.938 -94.588
Diluted Weighted Average Shares 437.457 428.382 403.644 400.06 397.992
Diluted EPS Excluding Extraordinary Items -0.31518 -0.27159 -0.2681 -0.2773 -0.23766
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.31518 -0.27042 -0.26603 -0.2773 -0.23766
Unusual Expense (Income) 0.681
Depreciation / Amortization 0.5 0.5 0.5 0.6 0.6
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 140.577 334.347 111.713 55.757 88.772
Cash and Short Term Investments 107.184 317.116 96.061 51.652 74.872
Cash & Equivalents 104.641 181.101 34.915 15.508 16.821
Short Term Investments 2.543 136.015 61.146 36.144 58.051
Total Receivables, Net 1.89 1.333 4.994 0.303 11.445
Prepaid Expenses 26.354 15.898 9.127 3.021 2.074
Other Current Assets, Total 5.149 1.531 0.781 0.381
Total Assets 362.356 468.91 221.381 143.123 181.95
Property/Plant/Equipment, Total - Net 189.582 119.167 90.679 72.23 76.885
Property/Plant/Equipment, Total - Gross 258.834 172.241 132.541 90.837 88.446
Accumulated Depreciation, Total -69.252 -53.074 -41.862 -18.607 -11.561
Intangibles, Net 20.003 1.42 1.463 0 0.565
Long Term Investments 0.84 0.822 8.799 10.75 14.201
Other Long Term Assets, Total 4.725 6.775 1.734 4.386 1.527
Total Current Liabilities 500.861 368.995 68.134 11.559 27.26
Accounts Payable 21.016 11.418 11.51 1.749 2.793
Accrued Expenses 43.058 54.398 38.806 8.549 21.104
Notes Payable/Short Term Debt 431.901 299.236 0 0 0
Other Current Liabilities, Total 3.469 3.943 1.559 0.504 2.398
Total Liabilities 809.683 711.083 341.189 22.444 35.944
Total Long Term Debt 241.335 306.349 254.353 0 5.945
Capital Lease Obligations 0.064 0 5.945
Deferred Income Tax 0.162 0.17 0
Other Liabilities, Total 69.98 37.317 17.214 10.885 2.739
Total Equity -447.327 -242.173 -119.808 120.679 146.006
Common Stock 0.042 0.04 0.038 0.01 0.008
Additional Paid-In Capital 1930.94 1719.7 1495.16 782.965 741.246
Retained Earnings (Accumulated Deficit) -2378.49 -1961.92 -1615.13 -662.191 -594.981
Other Equity, Total 0.183 0.004 0.122 -0.105 -0.267
Total Liabilities & Shareholders’ Equity 362.356 468.91 221.381 143.123 181.95
Total Common Shares Outstanding 421.405 397.666 382.079 98.4604 79.0877
Current Port. of LT Debt/Capital Leases 1.417 16.259 0.757 0.965
Accounts Receivable - Trade, Net 0
Note Receivable - Long Term 6.629 6.379 6.993
Long Term Debt 241.271 306.349 254.353
Minority Interest -2.493 -1.74 1.318
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 215.082 66.825 113.486 140.577 143.092
Cash and Short Term Investments 189.796 45.954 91.268 107.184 111.057
Cash & Equivalents 177.963 43.506 88.481 104.641 104.161
Short Term Investments 11.833 2.448 2.787 2.543 6.896
Total Receivables, Net 4.663 3.279 1.464 1.89 6.488
Accounts Receivable - Trade, Net
Prepaid Expenses 13.901 13.038 15.969 26.354 22.311
Other Current Assets, Total 6.722 4.554 4.785 5.149 3.236
Total Assets 432.419 291.227 343.4 362.356 352.943
Property/Plant/Equipment, Total - Net 187.887 194.138 198.471 189.447 176.87
Property/Plant/Equipment, Total - Gross 268.937 271.717 271.886 258.699 241.472
Accumulated Depreciation, Total -81.05 -77.579 -73.415 -69.252 -64.602
Intangibles, Net 18.467 18.992 19.502 20.003 20.471
Long Term Investments 0.817 0.841 0.82 0.84 0.811
Note Receivable - Long Term 6.816 6.753 6.691 6.629 6.566
Other Long Term Assets, Total 3.35 3.678 4.43 4.86 5.133
Total Current Liabilities 90.324 613.478 564.945 500.861 70.84
Accounts Payable 19.818 25.488 33.573 21.016 20.237
Accrued Expenses 66.896 68.319 56.605 43.058 43.579
Notes Payable/Short Term Debt 0 481.894 441.628 431.901 0
Current Port. of LT Debt/Capital Leases 2.338 36.618 30.207 1.417 2.461
Other Current Liabilities, Total 1.272 1.159 2.932 3.469 4.563
Total Liabilities 844.136 933.343 872.383 809.683 779.642
Total Long Term Debt 673.59 250.124 245.683 241.335 661.138
Long Term Debt 673.59 250.102 245.64 241.271 661.054
Deferred Income Tax
Minority Interest 1.072 -3.067 -2.733 -2.493 -2.382
Other Liabilities, Total 79.15 72.808 64.488 69.98 50.046
Total Equity -411.717 -642.116 -528.983 -447.327 -426.699
Common Stock 0.067 0.044 0.043 0.042 0.04
Additional Paid-In Capital 2315.72 1990.59 1965.84 1930.94 1843.72
Retained Earnings (Accumulated Deficit) -2728.29 -2632.71 -2494.83 -2378.49 -2270.27
Other Equity, Total 0.792 -0.04 -0.033 0.183 -0.19
Total Liabilities & Shareholders’ Equity 432.419 291.227 343.4 362.356 352.943
Total Common Shares Outstanding 667.539 440.51 435.759 421.405 400.304
Capital Lease Obligations 0 0.022 0.043 0.064 0.084
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -417.32 -349.848 -224.187 -160.158 -96.226
Cash From Operating Activities -337.509 -274.419 -171.724 -152.109 -63.381
Cash From Operating Activities 18.26 14.238 12.739 14.042 9.555
Deferred Taxes -0.004 -0.008 -2.938 -0.008 -0.498
Non-Cash Items 69.556 80.311 26.302 9.651 24.342
Cash Taxes Paid 0.002 0.009 0.008 0.003 0.004
Cash Interest Paid 35.442 2.106 0.04 0.019 0.475
Changes in Working Capital -8.001 -19.112 16.36 -15.636 -0.554
Cash From Investing Activities 27.297 -84.886 -19.812 18.552 57.101
Capital Expenditures -99.391 -33.563 -1.669 -4.287 -13.102
Other Investing Cash Flow Items, Total 126.688 -51.323 -18.143 22.839 70.203
Cash From Financing Activities 233.613 505.443 150.675 114.279 -0.771
Issuance (Retirement) of Stock, Net 59.885 165.927 86.975 66.609 -0.294
Issuance (Retirement) of Debt, Net 174.125 338.5 63.7 47.67 -0.477
Net Change in Cash -76.315 146.186 -40.886 -19.299 -7.051
Financing Cash Flow Items -0.397 1.016 0 0
Foreign Exchange Effects 0.284 0.048 -0.025 -0.021
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -116.583 -417.32 -308.994 -197.833 -102.998
Cash From Operating Activities -84.31 -337.509 -246.782 -166.182 -74.93
Cash From Operating Activities 4.681 18.26 13.034 8.534 4.09
Deferred Taxes -0.004
Non-Cash Items -0.078 69.556 50.589 35.808 14.366
Cash Taxes Paid 0 0.002 0.003 0 0
Cash Interest Paid 15.515 35.442 21 11.149 5.036
Changes in Working Capital 27.67 -8.001 -1.411 -12.691 9.612
Cash From Investing Activities -8.484 27.297 46.191 47.359 -69.313
Capital Expenditures -8.428 -99.391 -80.46 -64.525 -48.576
Other Investing Cash Flow Items, Total -0.056 126.688 126.651 111.884 -20.737
Cash From Financing Activities 76.888 233.613 123.673 -0.313 -0.298
Issuance (Retirement) of Stock, Net 47.057 59.885 -0.323 -0.313 -0.298
Issuance (Retirement) of Debt, Net 29.85 174.125 124.375 0 0
Foreign Exchange Effects -0.254 0.284 0.123 0.08 -0.175
Net Change in Cash -16.16 -76.315 -76.795 -119.056 -144.716
Financing Cash Flow Items -0.019 -0.397 -0.379

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

ImmunityBio, Inc. Company profile

ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.
Industry: Bio Therapeutic Drugs

3530 John Hopkins Court
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,573.47 Price
+1.790% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

XRP/USD

0.64 Price
+2.520% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading